Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Objective: Our objective was to estimate the prevalence and risk factors for long COVID symptoms among polymerase chain reaction–confirmed COVID-19 patients (hospitalised and community) in Malta.

Study design: This was a national cross-sectional survey among COVID-19 patients in Malta during 2020.

Methods: Patients were sent a questionnaire 3–6 months after testing positive. Data were analysed descriptively to estimate symptom prevalence, and multivariable logistic regressions were used to determine the risk factors for long COVID symptoms. Age, sex, initial symptoms, hospitalisation, and healthcare worker status were used as risk factors and symptoms (cough, shortness of breath, fatigue, anxiety, sadness, and memory loss) 2.5 months or more after COVID-19 onset were used as outcomes.

Results: Of 8446 eligible participants, 2665 (31.55%) responded with a median age of 37 years. Initial symptoms were reported in 82% of responders, and 7.73% were hospitalised. Among the long COVID symptoms, fatigue persisted among most non-hospitalised responders, whereas anxiety, shortness of breath, and sadness were the most common symptoms. Female sex, hospitalisation, and initial symptoms were associated with higher odds of fatigue, shortness of breath, cough, anxiety, sadness, and memory loss as long COVID symptoms.

Conclusions: Our study is the first to highlight long COVID symptoms and risk factors in Malta, showing that long COVID is common among hospitalised and non-hospitalised patients. These data should increase awareness of long COVID and facilitate support to those affected nationally.
Our questionnaire. Most characteristics were observed to be similarly cases in 2020, the eligible participants, and those who responded to pares the characteristics (age, gender, wave, and hospitalisation) of all during their initial COVID-19 episode. Supplementary Table 1com-

were female, and 7.73% of the responders had been hospitalised

Description of the data

Malta. Of these, 4643 records were excluded, and 2665 replies were received (response rate ¼ 31.55%; Fig. 1).

Fig. 1. Flowchart of inclusion and exclusion criteria of a national survey of long COVID in Malta.

Data analysis

Data were analysed descriptively to estimate symptom prevalence. Although no preselection strategy was used to adjust for response bias, the respondents’ age, gender and hospitalisation during the first and second waves were compared among all cases testing positive in Malta, those eligible to participate and the study responders. Specifically, the proportion of patients in each demographic group was compared descriptively to the sampling frame to assess potential data gaps or overrepresentation. Logistic regression was used to determine the risk factors for long COVID symptoms. Age, sex, wave number, healthcare worker status, initial symptoms, and hospitalisation due to COVID-19 were used as covariates. Symptoms persisting for more than 2.5 months from the COVID-19 episode were modelled as a dichotomous outcome on each model. Six models were fitted using the following outcomes: fatigue, shortness of breath, cough, anxiety, sadness and memory loss. All analyses were performed using R studio (R version: R 4.1.2)11.

Results

Response rate

There were 13,089 COVID-19 cases recorded during 2020 in Malta. Of these, 4643 records were excluded, and 2665 replies were received (response rate = 31.55%; Fig. 1). 

Description of the data

The median age was 37 years (interquartile range = 21 years), 56% were female, and 7.73% of the responders had been hospitalised during their initial COVID-19 episode. Supplementary Table 1 compares the characteristics (age, gender, wave, and hospitalisation) of all cases in 2020, the eligible participants, and those who responded to our questionnaire. Most characteristics were observed to be similarly represented in the three groups, signifying minimal selection and response bias.

Symptoms reported after isolation discharge from public health

The most common long COVID symptoms affecting more than 10% of respondents were anxiety, fatigue, and feeling of sadness (Supplementary Table 2). One in four patients (25.4%) persisted with at least one long COVID symptom, whereas 28.7% and 14.0% reported at least three or more and five or more long COVID symptoms, respectively. These numbers were higher among pa-

Risk factors for long COVID symptoms

Wavenumber was not associated with our discharge symptoms, and there was no significant interaction between age and hospitalisation. Female patients, initial hospital admission, and initial symptoms were associated with higher odds of fatigue, shortness of breath, cough, anxiety, sadness, and memory loss (Table 1). Participants in the 30–59 years age group were associated with higher odds of fatigue, cough, and memory loss than those in the less than 30 years age categories. However, there was no association between age and shortness of breath (Table 1). Conversely, patients aged 60 years were associated with lower odds of sadness and anxiety than those younger than 30 years (Table 1). Finally, healthcare workers were associated with lower odds of sadness than non-healthcare workers (Table 1).

Discussion

We evaluated the distribution of long COVID symptoms and their risk factors among COVID-19 patients diagnosed during the first year of the pandemic in Malta. We found that a large proportion of hospitalised and non-hospitalised COVID-19 patients presented with long COVID symptoms, and that as disease severity increased, patients had higher odds of presenting with long COVID.

Our study’s prevalence of long COVID symptoms was similar to other studies. For example, a study in Germany with a similarly low hospitalisation rate and follow-up time found that 9.7% and 8.6% of patients presented with fatigue and shortness of breath, respectively. In our study, female patients presented higher odds of long COVID symptoms than males (fatigue, shortness of breath, cough, anxiety, sadness and memory loss). Although patients in other re-

Younger age categories were associated with higher odds of anxiety and depression when compared with the older age categories. This was consistent with other studies carried out elsewhere. One study linked these observations to increased use of social media by younger age groups, which could lead to more exposure to news about COVID-19. Another possible explanation accounting for the differences between age groups could be the different presentation of sadness and anxiety in older persons, leading to misdiagnosis by clinicians and lack of awareness by the sufferers themselves.

Conversely, people in the 30–59 years age category had higher odds of developing fatigue, cough, and memory loss than those younger than 30 years. This is not surprising, given that those in the 30–59 years age category tend to have more severe symptoms than
those in the younger category. Studies reviewed in the literature indicated that older patients had a higher risk of developing long COVID-19 symptoms;8 however, our study did not show similar results. Although lack of association does not prove independence, it is still reasonable to consider socio-economic factors and access to health care as potential risk factors for long COVID. And fourth, as no COVID-19 vaccinations were available at the time, our study population was limited to unvaccinated individuals.

Our study had several strengths. First, except for some large registry-based studies similar to the one by Estiri et al.,10 most studies have a smaller sample size. Second, we presented data from a national survey, and national data can leverage policy when presented to decision-makers. Third, we used a comprehensive sampling frame that allowed us to identify differences between respondents and non-respondents, which can help identify potential sources of bias.

It is essential to understand the characteristics and risk factors for long COVID to effectively communicate with the local population. In addition, the associations between hospitalisation and symptom-severity with long COVID symptoms are important for follow-up of discharged COVID-19 patients and resource allocation. National evidence-based decisions could aid in COVID-19 case management, helping increase clinicians’ awareness regarding long COVID, offering support to COVID-19 survivors to re-establish their pre-COVID, offering support to COVID-19 survivors to re-establish their pre-COVID-19 health.

### Author statements

#### Ethical approval

Ethical approval for this study (HEC18/2020) was obtained from the Health Ethics Committee, Malta.

### Table 1

Multivariable analysis (odds ratio [95% confidence interval]) of risk factors for fatigue, shortness of breath, cough, memory loss, anxiety, and sadness as long COVID symptoms from a national survey in Malta (N = 2665).

| Risk factor | Fatigue | Shortness of breath | Cough |
|-------------|---------|---------------------|-------|
|             | N (%)   | 258 (9.7%)          | 225 (7.8%) |
|             | OR      | OR                  | OR    |
|             | P-value | <0.01               | <0.01 |
| Hospitalisation (no) | Ref     | Ref                 | Ref   |
| Yes         | 2459 (92.3%) | 2.00 (1.17-3.37) | <0.01 |
| Sex (female) | 206 (7.7%) | 3.36 (2.37-4.71) | <0.01 |
| Male        | 1493 (56.0%) | 0.41 (0.31-0.53) | <0.01 |
| Initial symptoms (no) | 475 (17.8%) | 0.45 (0.29-0.68) | <0.01 |
| Yes         | 2190 (82.2%) | 2.61 (1.75-4.05) | 1.2 |
| Age (<30)   | 771 (28.0%) | Ref                 | Ref   |
| 30–59       | 1615 (60.6%) | 1.25 (0.96-1.65) | 0.11  |
| >59         | 279 (10.5%) | 0.82 (0.49-1.31) | 0.41  |

| Risk factor | Memory loss | Anxiety | Sadness |
|-------------|-------------|---------|---------|
|             | N (%)       | 147 (5.5%) | 293 (11.0%) |
|             | OR          | OR      | OR      |
|             | P-value     | <0.01   | <0.01   |
| Hospitalisation (no) | Ref     | Ref     | Ref     |
| Yes         | 2459 (92.3%) | 3.34 (2.31-4.77) | <0.01 |
| Sex (female) | 206 (7.7%) | 0.35 (0.26-0.47) | <0.01 |
| Male        | 1493 (56.0%) | 0.41 (0.31-0.54) | <0.01 |
| Initial symptoms (no) | 475 (17.8%) | 2.74 (1.77-4.47) | <0.01 |
| Yes         | 2190 (82.2%) | 3.15 (2.09-4.97) | 0.11  |
| Age (<30)   | 771 (28.9%) | Ref     | Ref     |
| 30–59       | 1615 (60.6%) | 1.26 (0.95-1.68) | 0.11  |
| >59         | 279 (10.5%) | 0.48 (0.25-0.85) | 0.02  |
| Healthcare worker (no) | 2401 (90.1%) | Ref     | Ref     |
| Yes         | 264 (9.9%) | 0.7 (0.43-1.08) | 0.58  |

OR, odds ratio.
Funding

No funding was available for this study.

Competing interests

None declared.

Acknowledgements

None.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.puhe.2022.09.021.

References

1. World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus. WHO; 2020.
2. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep 2021;11(1):1–14.
3. Augustin M, Schommers P, Stecher M, Dewald F, Gieselmann L, Gruell H, et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. Lancet Reg Heal - Eur. 2021;6:1–8.
4. Sykes DL, Holdsworth L, Jawad N, Gunasekera P, Morice AH, Crooks MG. Post-COVID-19 symptom burden: what is long-COVID and how should we manage it? Lung 2021;199(2):113–9. https://doi.org/10.1007/s00408-021-00423-z. Available from.
5. Nwachukwu I, Nkire N, Shalaby R, Hrabok M, Vuong W, Guszowski A, et al. COVID-19 pandemic: age-related differences in measures of stress, anxiety and depression in Canada. Int J Environ Res Publ Health 2020;17:6366. 2020 Sep;17(17):6366.
6. Ozamiz-Etxebarria N, Donsil-Santamaria M, Picaza-Gorrochategui M, Idiagia-Mondragon N. Stress, anxiety, and depression levels in the initial stage of the COVID-19 outbreak in a population sample in the northern Spain. Cad Saude Publica 2020;36(4).
7. Christensen H, Jorm AF, Mackinnon AJ, Korten AE, Jacomb PA, Henderson AS, et al. Age differences in depression and anxiety symptoms: a structural equation modelling analysis of data from a general population sample. Psychol Med 1999;29(2):325–39.
8. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nat Med 2021;27(4):626–31. 2021 274.
9. Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis (Auckl) 2021;53(10):737–54. Available from: https://doi.org/10.1080/23744235.2021.1924397.
10. Estiri H, Strasser ZH, Brat GA, Semenov YR. (4CE) TC for C of C 19 by E, Patel CJ, et al. Evolving Phenotypes of non-hospitalized Patients that Indicate Long Covid. medRxiv 2021;25:21255923. 2021.04.
11. R Core Team (2021). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https://www.R-project.org.